Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by chipmuki1234567on May 26, 2017 12:12am
134 Views
Post# 26286540

RE:RE:John Wallace & Co.

RE:RE:John Wallace & Co.

StrikingMoose wrote: Probably thought citagenix was going to go a lot better than it is. I think the major driving issue is money. If you read recent reports on sedar the risks are all mostly centered around money. They run continuous deficits which one would assume they would as they're hedging their bets that 346 will be a success and they'll pocket a LOT of money on a partnership once they prove it's GI safe with no side effects. I don't think anyone is happy about this PP but this is what's happening so may as well pull up our pants and get behind it and try see the bright side. Yes there will be dilution. If you have money to participate or average down in the floating market here's your chance. The science of their drugs is still solid but trials are super expensive and that's what's fuccing it all up. The last 2 weeks with a couple big holders continuously dropping the price anytime it climbed back to 16-17 seems suspicious of keeping the price down to affect the offer price of the PP. Maybe I am just paranoid and suspicious of everything. All we can do is sit tight and wait. I am way deeper into the red than I ever thought I'd be with this company. I'm not going to panic and sell though as no one else should. It's just a waiting game now unfortunately. June will be bad but once we get confirmation of trial starting in July then we will hopefully worm our way back up.


Umm no.. being a shareholder is not about keeping mum and letting managers run a circus.. Saying Citagenix is forecasted to do a lot better is not really acceptable.. fix it or sell it instead of raising money in the market via dilution.. you can probably get the $3M to finish the trial, if you are so convinced there is a major partnership coming...

About partnership.. lets see... knight pharma took them to the cleaners.. they paraded a paltry $1M licensing deal as a success.. claiming it validated something (If it validated anything, they would have got a lot more for a NSAID)... this is the same guy whose science failed in the 1990s with Nico-Ox....

They have consistently over promised and under delivered.. but hey John Wallace has a heck of a sense of humor about... "My Phase 1 trial had issues, but we got read of that pesky lawyer"... gut citagenix and bring down salaries and bonuses.. thats whats killing the cash flow.. go see the income statement..

Guys, be a bit demanding instead of a teletubby as you watch a company being mismanaged... stocks are not supposed to be gambling till we turned it into one...


 

 

Bullboard Posts